Given the co-morbidities associated with supra-physiologic doses of corticosteroids, what is the rationale for inhibiting the hypothalamic-pituitary-adrenal axis upstream, by using the CRF1 receptor antagonist crinecerfont?
Given the co-morbidities associated with supra-physiologic doses of corticosteroids, what is the rationale for inhibiting the hypothalamic-pituitary-adrenal axis upstream, by using the CRF1 receptor antagonist crinecerfont?
Medical Director, DSD Program Medical Director, CAH Program Co-Director, Turner Syndrome Clinic Seattle Children’s Hospital Professor of Pediatrics University of Washington School of Medicine Seattle, WA
